MediciNova (NASDAQ:MNOV) Research Coverage Started at HC Wainwright

HC Wainwright initiated coverage on shares of MediciNova (NASDAQ:MNOV) in a report released on Monday morning, MarketBeat reports. The brokerage issued a buy rating and a $10.00 target price on the biopharmaceutical company’s stock. HC Wainwright also issued estimates for MediciNova’s Q1 2026 earnings at ($0.06) EPS, Q2 2026 earnings at ($0.06) EPS, Q3 2026 earnings at ($0.06) EPS, Q4 2026 earnings at ($0.08) EPS, FY2026 earnings at ($0.26) EPS, FY2027 earnings at ($0.43) EPS, FY2028 earnings at $0.29 EPS, FY2029 earnings at $1.90 EPS and FY2030 earnings at $3.02 EPS.

Other analysts have also recently issued research reports about the company. D. Boral Capital reissued a “buy” rating and issued a $9.00 price objective on shares of MediciNova in a research report on Friday, January 30th. Lucid Cap Mkts raised MediciNova to a “strong-buy” rating in a research report on Monday, January 5th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of MediciNova in a research note on Monday, December 29th. Two analysts have rated the stock with a Strong Buy rating, two have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $8.00.

MediciNova Stock Down 4.1%

NASDAQ:MNOV opened at $1.41 on Monday. The stock has a market capitalization of $69.40 million, a price-to-earnings ratio of -5.87 and a beta of 0.58. MediciNova has a 52 week low of $1.13 and a 52 week high of $1.96. The firm has a 50 day moving average of $1.54 and a 200 day moving average of $1.42.

MediciNova (NASDAQ:MNOV) last released its quarterly earnings results on Friday, February 20th. The biopharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.10) by $0.05. The firm had revenue of $0.15 million during the quarter. As a group, analysts expect that MediciNova will post -0.24 EPS for the current year.

Institutional Investors Weigh In On MediciNova

Several institutional investors and hedge funds have recently made changes to their positions in MNOV. State Street Corp increased its position in shares of MediciNova by 10.9% in the 4th quarter. State Street Corp now owns 193,698 shares of the biopharmaceutical company’s stock valued at $254,000 after acquiring an additional 19,100 shares during the period. Jane Street Group LLC acquired a new stake in MediciNova during the 4th quarter worth about $214,000. StoneX Group Inc. acquired a new stake in MediciNova during the 4th quarter worth about $25,000. Goldman Sachs Group Inc. purchased a new stake in MediciNova during the 4th quarter valued at about $35,000. Finally, Citadel Advisors LLC purchased a new stake in MediciNova during the 3rd quarter valued at about $92,000. 9.90% of the stock is currently owned by institutional investors and hedge funds.

MediciNova News Summary

Here are the key news stories impacting MediciNova this week:

• Positive Sentiment: HC Wainwright initiated coverage with a “Buy” rating and a $10 price target, a material bullish endorsement for a small-cap biotech that can attract new investor attention and trading interest. HC Wainwright Initiates Coverage on MediciNova (NASDAQ:MNOV)
• Positive Sentiment: The analyst model projects multi-year upside: HC Wainwright’s forecasts show MediciNova moving from near-term losses to profitability (projected EPS of $0.29 in FY2028, $1.90 in FY2029 and $3.02 in FY2030). That long-term earnings runway supports the high $10 target and could justify speculative buying by growth-oriented investors. HC Wainwright & Co. initiates coverage of MediciNova (MNOV) with buy recommendation
• Neutral Sentiment: HC Wainwright’s near-term quarterly estimates remain negative (Q1–Q3 2026: ~$0.06 loss per share; Q4 2026: ~$0.08 loss), and FY2026 is modeled at a loss — meaning any upside depends on successful execution and clinical/commercial progress rather than immediate earnings improvement.
• Negative Sentiment: Despite the bullish initiation, the stock is down today—likely reflecting that the market is weighing near-term negative EPS, small market cap/liquidity and skepticism over execution risk before the multi-year upside can be realized. Volume is modest and technicals (50/200-day moving averages near the current price) suggest limited conviction so far.

MediciNova Company Profile

MediciNova, Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel small-molecule therapeutics for neurodegenerative, inflammatory, fibrotic and oncological diseases. Founded in the late 1990s, the company advances its proprietary compounds through clinical trials and strategic partnerships, with a goal of addressing areas of high unmet medical need. MediciNova is headquartered in San Diego, California, and maintains a presence in Tokyo to support collaborations and regulatory interactions in Asian markets.

The company’s leading clinical asset, MN-166 (ibudilast), is an anti-inflammatory and neuroprotective agent originally approved in Japan for asthma and post-stroke dizziness.